Alpha 2.0
Login Register
» Authors » Robert Lang

Robert Lang

Explore the profile of Robert Lang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 46
Followers 0
Related Specialties
Biochemistry
Endocrinology
Oncology
Top 10 Co-Authors
Uwe Kobold
Michael Vogeser
Inaam A Nakchbandi
Barbara Kinder
Andreas Leinenbach
Magdalena Swiatek-de Lange
Johann Karl
Vinzent Rolny
Hans Krause
Thomas Duelffer
Published In
J Clin Endocrinol Metab
Clin Chim Acta
Tumour Biol
Affiliations
Soon will be listed here.
Recent Articles
1.
Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness
Lang R, Rolny V, Leinenbach A, Karl J, Lange M, Kobold U, et al.
Tumour Biol . 2019 Mar; 41(3):1010428319827223. PMID: 30907281
Prostate cancer represents a major cause of cancer death in men worldwide. Novel non-invasive methods are still required for differentiation of non-aggressive from aggressive tumors. Recently, changes in prostate-specific antigen...
2.
An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example
Lang R, Leinenbach A, Karl J, Lange M, Kobold U, Vogeser M
Clin Chim Acta . 2018 Feb; 480:1-8. PMID: 29408166
Recently, site-specific fucosylation of glycoproteins has attracted attention as it can be associated with several types of cancers including prostate cancer. However, individual glycoproteins, which might serve as potential cancer...
3.
An LC-MS/MS based candidate reference method for the quantification of total gentamicin in human serum and plasma using NMR characterized calibrator material
Lucha S, Taibon J, Pongratz S, Geletneky C, Huber E, Wintterle-Roehm C, et al.
Clin Chim Acta . 2016 Nov; 464:211-217. PMID: 27871844
Background: Accurate measurement of gentamicin concentration in serum and plasma is required for therapeutic drug monitoring to ensure appropriate treatment of patients. In this work, we present a validated LC-MS/MS-based...
4.
The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism
Nakchbandi I, Lang R, Kinder B, Insogna K
J Clin Endocrinol Metab . 2007 Dec; 93(3):967-73. PMID: 18073309
Context: The mechanisms of action of PTH on bone in vivo remain incompletely understood. The objective of this investigation was to examine changes in serum levels of receptor activator of...
5.
Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism
Nakchbandi I, Mitnick M, Lang R, Gundberg C, Kinder B, Insogna K
J Clin Endocrinol Metab . 2002 Nov; 87(11):4946-51. PMID: 12414855
It remains unclear whether mild primary hyperparathyroidism results in accelerated bone loss, with recent studies reaching different conclusions. This could be due to intrinsic differences in disease activity not captured...